Evidence map›Paper›PMID 26491864›Full record

ArticleCritical care medicine2016

Inhibition of Adenosine Kinase Attenuates Acute Lung Injury.

David Köhler, Ariane Streienberger, Julio C Morote-García, Tiago F Granja, Mariella Schneider, Andreas Straub, Detlev Boison, Peter Rosenberger

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04410328 (A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04410328 phase3completednot on this mapstarted 2020, after this paper: background citation

A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection

TypeinterventionalSponsorRutgers, The State University of New JerseyRan2020 to 2021Enrolled98ConditionsCovid19ArmsDipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Therapeutic potential of adenosine kinase inhibition-Revisited.Pharmacology research & perspectives · 2019
    Review
  10. Review
  11. Purinergic Signalling: Therapeutic Developments.Frontiers in pharmacology · 2017
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

David Köhler1Department of Anaesthesiology and Intensive Care Medicine, Tübingen University Hospital, Eberhard-Karls University Tübingen, Tübingen, Germany. 2Department of Neurology, Neurobiology Laboratories, Legacy Research Institutes, Portland, OR.
Ariane Streienberger
Julio C Morote-García
Tiago F Granja
Mariella Schneider
Andreas Straub
Detlev Boison
Peter Rosenberger
Apple (Israel) · IL

Funding

Adenosine and schizophrenia: mechanisms and therapiesR01MH083973 · NIMH · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI BOISON, DETLEV · 2009 to 2015
$2.5M
Adenosine kinase antisense gene therapy for temporal lobe epilepsy.R21NS088024 · NINDS · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI BOISON, DETLEV · 2015 to 2016
$825k
NIMH NIH HHS R01 MH083973NINDS NIH HHS R21 NS088024
6 · The paper itself

Abstract

objectivesExtracellular adenosine has tissue-protective potential in several conditions. Adenosine levels are regulated by a close interplay between nucleoside transporters and adenosine kinase. On the basis of the evidence of the role of adenosine kinase in regulating adenosine levels during hypoxia, we evaluated the effect of adenosine kinase on lung injury. Furthermore, we tested the influence of a pharmacologic approach to blocking adenosine kinase on the extent of lung injury.

designProspective experimental animal study.

settingUniversity-based research laboratory. SUBJECTS: In vitro cell lines, wild-type and adenosine kinase+/- mice.

interventionsWe tested the expression of adenosine kinase during inflammatory stimulation in vitro and in a model of lipopolysaccharide inhalation in vivo. Studies using the adenosine kinase promoter were performed in vitro. Wild-type and adenosine kinase+/- mice were subjected to lipopolysaccharide inhalation. Pharmacologic inhibition of adenosine kinase was performed in vitro, and its effect on adenosine uptake was evaluated. The pharmacologic inhibition was also performed in vivo, and the effect on lung injury was assessed. MEASUREMENTS AND MAIN

resultsWe observed the repression of adenosine kinase by proinflammatory cytokines and found a significant influence of nuclear factor kappa-light-chain-enhancer of activated B-cells on regulation of the adenosine kinase promoter. Mice with endogenous adenosine kinase repression (adenosine kinase+/-) showed reduced infiltration of leukocytes into the alveolar space, decreased total protein and myeloperoxidase levels, and lower cytokine levels in the alveolar lavage fluid. The inhibition of adenosine kinase by 5-iodotubercidin increased the extracellular adenosine levels in vitro, diminished the transmigration of neutrophils, and improved the epithelial barrier function. The inhibition of adenosine kinase in vivo showed protective properties, reducing the extent of pulmonary inflammation during lung injury.

conclusionsTaken together, these data show that adenosine kinase is a valuable target for reducing the inflammatory changes associated with lung injury and should be pursued as a therapeutic option.

Indexed as

Acute Lung InjuryAdenosine KinaseAnimalsB-LymphocytesBronchoalveolar Lavage FluidCell LineCytokinesLipopolysaccharidesLungMicePneumoniaProspective StudiesTubercidin5-iodotubercidinAdenosine KinaseCytokinesLipopolysaccharidesTubercidin

Identifiers

PMID26491864
PMCPMC4792660
OpenAlexW2331695696

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.